Anixa Biosciences (ANIX) Competitors $4.47 +0.14 (+3.23%) Closing price 04:00 PM EasternExtended Trading$4.49 +0.02 (+0.34%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANIX vs. CTMX, RGNX, MNPR, PRTA, ETON, GOSS, CRVS, ARCT, ESPR, and ORGOShould you be buying Anixa Biosciences stock or one of its competitors? The main competitors of Anixa Biosciences include CytomX Therapeutics (CTMX), REGENXBIO (RGNX), Monopar Therapeutics (MNPR), Prothena (PRTA), Eton Pharmaceuticals (ETON), Gossamer Bio (GOSS), Corvus Pharmaceuticals (CRVS), Arcturus Therapeutics (ARCT), Esperion Therapeutics (ESPR), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical products" industry. Anixa Biosciences vs. Its Competitors CytomX Therapeutics REGENXBIO Monopar Therapeutics Prothena Eton Pharmaceuticals Gossamer Bio Corvus Pharmaceuticals Arcturus Therapeutics Esperion Therapeutics Organogenesis CytomX Therapeutics (NASDAQ:CTMX) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations. Does the media prefer CTMX or ANIX? In the previous week, CytomX Therapeutics had 6 more articles in the media than Anixa Biosciences. MarketBeat recorded 10 mentions for CytomX Therapeutics and 4 mentions for Anixa Biosciences. CytomX Therapeutics' average media sentiment score of 0.60 beat Anixa Biosciences' score of 0.20 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Anixa Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, CTMX or ANIX? CytomX Therapeutics has a beta of 2.27, indicating that its stock price is 127% more volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Which has better valuation and earnings, CTMX or ANIX? CytomX Therapeutics has higher revenue and earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytomX Therapeutics$138.10M4.07$31.87M$0.566.09Anixa Biosciences$210K700.73-$12.55M-$0.35-12.77 Is CTMX or ANIX more profitable? CytomX Therapeutics has a net margin of 34.04% compared to Anixa Biosciences' net margin of 0.00%. CytomX Therapeutics' return on equity of 158.70% beat Anixa Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets CytomX Therapeutics34.04% 158.70% 36.04% Anixa Biosciences N/A -67.45%-59.18% Do analysts prefer CTMX or ANIX? CytomX Therapeutics presently has a consensus target price of $5.42, suggesting a potential upside of 58.85%. Anixa Biosciences has a consensus target price of $9.00, suggesting a potential upside of 101.34%. Given Anixa Biosciences' higher possible upside, analysts plainly believe Anixa Biosciences is more favorable than CytomX Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytomX Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Anixa Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders and institutionals have more ownership in CTMX or ANIX? 67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 6.6% of CytomX Therapeutics shares are owned by company insiders. Comparatively, 25.3% of Anixa Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryCytomX Therapeutics beats Anixa Biosciences on 14 of the 17 factors compared between the two stocks. Get Anixa Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANIX vs. The Competition Export to ExcelMetricAnixa BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$142.53M$3.40B$6.05B$10.51BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-12.7722.9285.4427.36Price / Sales700.73270.00515.26195.91Price / CashN/A46.9537.5761.53Price / Book7.5810.5512.426.82Net Income-$12.55M-$52.58M$3.32B$276.89M7 Day Performance0.68%1.09%1.01%0.27%1 Month Performance26.99%16.09%10.75%8.31%1 Year Performance47.52%18.41%76.20%35.60% Anixa Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANIXAnixa Biosciences2.8515 of 5 stars$4.47+3.2%$9.00+101.3%+42.0%$142.53M$210K-12.775News CoverageAnalyst ForecastCTMXCytomX Therapeutics4.2324 of 5 stars$3.40+1.2%$5.42+59.3%+213.8%$554.11M$138.10M6.07170RGNXREGENXBIO4.392 of 5 stars$11.34+3.8%$28.38+150.2%+10.3%$551.61M$83.33M-3.30370MNPRMonopar Therapeutics2.6799 of 5 stars$102.05+16.2%$105.67+3.5%+1,667.9%$541.85MN/A-30.6510Analyst ForecastGap UpPRTAProthena3.2748 of 5 stars$10.35+3.0%$20.50+98.1%-41.6%$540.99M$135.16M-1.84130ETONEton Pharmaceuticals2.6839 of 5 stars$18.08-8.0%$29.67+64.1%+129.2%$527.23M$39.01M-113.0020GOSSGossamer Bio3.8305 of 5 stars$2.44+7.0%$8.50+248.4%+152.7%$518.43M$114.70M-3.94180Gap UpCRVSCorvus Pharmaceuticals2.1935 of 5 stars$7.11+2.6%$13.75+93.4%+3.7%$516.38MN/A-7.0430News CoverageAnalyst ForecastARCTArcturus Therapeutics2.8856 of 5 stars$19.39+2.3%$50.57+160.8%+1.6%$514.58M$152.31M-8.70180News CoverageAnalyst UpgradeESPREsperion Therapeutics3.7618 of 5 stars$2.72+7.5%$7.00+157.4%+29.2%$510.11M$332.31M-5.55200ORGOOrganogenesis3.7369 of 5 stars$3.95-0.3%$7.33+85.7%+29.4%$502.36M$482.04M-28.21950 Related Companies and Tools Related Companies CytomX Therapeutics Alternatives REGENXBIO Alternatives Monopar Therapeutics Alternatives Prothena Alternatives Eton Pharmaceuticals Alternatives Gossamer Bio Alternatives Corvus Pharmaceuticals Alternatives Arcturus Therapeutics Alternatives Esperion Therapeutics Alternatives Organogenesis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANIX) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
